Spector, Roseman & Kodroff, P.C. Announces the Filing of a Class Action Suit Against Vicuron Pharmaceuticals
08 July 2004 - 2:52AM
PR Newswire (US)
Spector, Roseman & Kodroff, P.C. Announces the Filing of a
Class Action Suit Against Vicuron Pharmaceuticals PHILADELPHIA,
July 7 /PRNewswire/ -- The law firm of Spector, Roseman &
Kodroff, P.C. announces that a class action lawsuit was commenced
in the United States District Court for the Eastern District of
Pennsylvania, on behalf of purchasers of the securities of Vicuron
Pharmaceuticals, Inc. ("Vicuron" or the "Company") (NASDAQ:MICU)
between March 17, 2003 through May 24, 2004, inclusive (the "Class
Period"). The Complaint alleges that defendants violated the
federal securities laws by issuing materially false and misleading
statements contained in press releases and filings with the
Securities and Exchange Commission during the Class Period.
Specifically, the Complaint alleges that during the Class Period,
defendants artificially inflated the price of Vicuron stock by
concealing critical material information regarding the details of
both the safety and efficacy of anidulafungin. Defendants concealed
key adverse information regarding the development and
commercialization of anidulafungin, raising serious concerns for
the very approval of the drug for the treatment of esophageal
candidiasis and other selected indications. If you purchased
Vicuron securities during the Class Period, you may, no later than
August 16, 2004, move to be appointed as a Lead Plaintiff in this
class action. A Lead Plaintiff is a representative, chosen by the
Court, that acts on behalf of other class members in directing the
litigation. The Private Securities Litigation Reform Act of 1995
directs Courts to assume that the class member(s) with the "largest
financial interest" in the outcome of the case will best serve the
class in this capacity. Courts have discretion in determining which
class member(s) have the "largest financial interest," and have
appointed Lead Plaintiffs with substantial losses in both absolute
terms and as a percentage of their net worth. If you have sustained
substantial losses in Vicuron securities during the Class Period,
please contact Spector, Roseman & Kodroff, P.C. at for a more
thorough explanation of the Lead Plaintiff selection process. If
you have relatively small losses, your ability to participate in
any recovery will be protected by the Lead Plaintiff(s), and you
need take no affirmative steps at this time. If you wish to join
this action, please visit
http://www.srk-law.com/dbjoinaclassaction.asp. If you wish to
discuss this action or have any questions concerning this notice or
your rights or interests, please contact plaintiff's counsel Robert
M. Roseman toll-free at 888-844-5862 or via e-mail at . For more
detailed information about the firm please visit its website at
http://www.srk-law.com/. Spector, Roseman & Kodroff, P.C.,
located in Philadelphia, Pennsylvania, concentrates its practice in
complex litigation including actions dealing with securities laws,
antitrust, contract and commercial claims. The firm is active in
major litigation pending in federal and state courts throughout the
United States. The firm's reputation for excellence has been
recognized on repeated occasions by courts which have appointed the
firm as lead counsel in numerous major class actions involving
violations of the federal securities laws and the federal antitrust
laws, and consumer fraud. As a result of the efforts of the firm,
and its members, hundreds of millions of dollars have been
recovered on behalf of thousands of defrauded shareholders and
companies. DATASOURCE: Spector, Roseman & Kodroff, P.C.
CONTACT: Robert M. Roseman of Spector, Roseman & Kodroff, P.C.,
+1-888-844-5862 Web site: http://www.srk-law.com/
http://www.srk-law.com/dbjoinaclassaction.asp
Copyright
Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Vicuron Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More Vicuron Pharmaceuticals (MM) News Articles